Aurora Cannabis partners with Vectura Fertin Pharma to launch CBD lozenge
Agreement has an initial term of 24 months
Partnership will initially see launch of a new CBD lozenge from Cogent International, a Vectura Fertin Pharma subsidiary, on Aurora's Canadian medical cannabis platform
Aurora Cannabis has partnered with Vectura Fertin Pharma to introduce a new CBD lozenge on the Canadian medical cannabis market. The agreement has an initial term of 24 months with a target of launching CBD-containing products on Aurora's Canadian medical cannabis platform.
The initial launch will see the introduction of a new CBD lozenge from Cogent International, a Vectura Fertin Pharma subsidiary. The lozenge will be available in a variety of strengths and flavors.
Aurora Cannabis is a leading global cannabis company that serves both the medical and recreational markets. Vectura Fertin Pharma is a leading provider of respiratory and other specialty pharmaceuticals.
Comments